MENU
NVAX
AS OF
Feb 3 closing price
Price
$8.37
Change
-$0.22 (-2.56%)
Capitalization
1.36B
28 days until earnings call
Intraday BUY SELL Signals
+Compare
NVAX
Stock ticker: NASDAQ
AS OF
Feb 3 closing price
Price
$8.37
Change
-$0.22 (-2.56%)
Capitalization
1.36B

NVAX Novavax Forecast, Technical & Fundamental Analysis

Novavax Inc is a biotechnology company that develops vaccines... Show more

Industry: #Biotechnology
NVAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for NVAX with price predictions
Feb 02, 2026

NVAX saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for NVAX moved out of overbought territory on January 30, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 50 similar instances where the indicator exited the overbought zone. In of the 50 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for NVAX moved out of overbought territory on January 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on February 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NVAX broke above its upper Bollinger Band on January 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

NVAX moved above its 50-day moving average on January 05, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for NVAX crossed bullishly above the 50-day moving average on January 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 111 cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.223) is normal, around the industry mean (27.778). P/E Ratio (4.164) is within average values for comparable stocks, (51.342). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.892). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (1.307) is also within normal values, averaging (333.006).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
NVAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

NVAX is expected to report earnings to fall 60.98% to -48 cents per share on March 04

Novavax NVAX Stock Earnings Reports
Q4'25
Est.
$-0.49
Q3'25
Missed
by $0.71
Q2'25
Beat
by $0.68
Q1'25
Beat
by $3.36
Q4'24
Beat
by $0.09
The last earnings report on November 06 showed earnings per share of -125 cents, missing the estimate of -54 cents. With 3.78M shares outstanding, the current market capitalization sits at 1.36B.
A.I. Advisor
published General Information

General Information

a company which engages in development of novel recombinant vaccines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
700 Quince Orchard Road
Phone
+1 240 268-2000
Employees
1534
Web
https://www.novavax.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OGINX48.740.06
+0.12%
Invesco Global Opportunities R
NAWCX48.51-0.01
-0.02%
Voya Global High Dividend Low Vol C
OFSCX18.91-0.06
-0.32%
Olstein Strategic Opportunities C
PIODX45.57-0.22
-0.48%
Victory Pioneer A
PARNX53.51-1.12
-2.05%
Parnassus Mid Cap Growth Investor

NVAX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-1.75%
MRNA - NVAX
57%
Loosely correlated
-3.45%
BNTX - NVAX
45%
Loosely correlated
-4.28%
FHTX - NVAX
42%
Loosely correlated
+2.45%
CRSP - NVAX
38%
Loosely correlated
+2.70%
AURA - NVAX
38%
Loosely correlated
+5.00%
More